Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew burns indication for Versajet:

This article was originally published in Clinica

Executive Summary

The US FDA has given Smith & Nephew 510(k) market clearance to expand the use of its hydrosurgery debridement system to the treatment of burns. The Versajet device is a waterjet-powered system that enables surgeons to simultaneously grasp, cut and remove damaged tissue and contaminants precisely, without collateral tissue damage associated with current surgical treatment methods, claims the firm. It was previously cleared for removing dead tissue from a wide variety of other wounds, including chronic and acute wounds. "The expansion of Versajet's labelling provides another avenue of growth for Smith & Nephew," said Joe Woody, president of the firm's Hull, UK-based advanced wound management division.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel